Related Experiment Video
Updated: Sep 7, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Hyperkalemia due to low-molecular-weight heparin]
Wendy van der Heiden1, J J E Bart Koopman1, Natasha M Appelman-Dijkstra2
1LUMC, Leiden. Afd. Interne Geneeskunde.
Low-molecular-weight heparin (LMWH) can cause hyperkalemia, a condition often linked to iatrogenic causes. Physicians should consider LMWH, like nadroparin, when evaluating patients with unexplained high potassium levels.
Area of Science:
- Nephrology
- Pharmacology
- Internal Medicine
Background:
- Hyperkalemia is frequently iatrogenic, necessitating a thorough review of patient prescriptions.
- Low-molecular-weight heparin (LMWH) is not commonly recognized as a cause of hyperkalemia.
Observation:
- A patient with pancreatitis developed severe hyperkalemia, with investigations suggesting hypoaldosteronism.
- Nadroparin, an LMWH, was prescribed for venous thrombosis and identified as the potential cause of hyperkalemia.
Findings:
- Biochemical testing confirmed hypoaldosteronism.
- A rechallenge with nadroparin led to a rapid increase in serum potassium, confirming the drug's role.
Implications:
- Hypoaldosteronism should be considered in patients using LMWH who develop hyperkalemia.
- Monitoring potassium levels is advisable for patients on LMWH, especially those with other hyperkalemia risk factors.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antihypertensive Drugs: Potassium-Sparing Diuretics
Hemodialysis II: Procedure and Complications
Depolarizing Blockers: Pharmocokinetics
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Cardiac Catheterization I: Pre-Procedure Overview

